PCN25 COST-EFFECTIVENESS OF NIVOLUMAB IN FIRST-LINE TREATMENT OF ADVANCED MELANOMA REGARDLESS OF BRAF MUTATION STATUS FROM A BRAZILIAN PUBLIC HEALTHCARE SYSTEM
Abstract
Authors
J.P.D.S.N. Lima P. Marinheiro G. Bernardino